STOCK TITAN
  1. Home
  2. News
  3. FUSN

Fusion Pharmaceuticals To Present At The Cowen 41st Annual Health Care Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

HAMILTON, ON and BOSTON, Feb. 23, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in the "Novel Oncology Targets" panel discussion at the Cowen 41st Annual Health Care Conference on Monday, March 1, 2021 at 1:20pm EST. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D.

About Fusion
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion connects alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434, is currently in a Phase 1 clinical trial. The Company is advancing a pipeline of targeted radiopharmaceutical cancer therapies for a broad array of tumor types based upon its proprietary platform technology.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-present-at-the-cowen-41st-annual-health-care-conference-301233848.html

SOURCE Fusion Pharmaceuticals Inc.

Stock FUSN logo
Fusion Pharmaceuticals Inc

NASDAQ:FUSN

FUSN Rankings

#1945 Ranked by Market Cap
#282 Ranked by Stock Gains
N/A Ranked by Dividends

FUSN Latest News

Apr 25, 2024
Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order
Apr 9, 2024
Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024
Mar 20, 2024
Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates
Mar 19, 2024
Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer
Mar 6, 2024
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FUSN Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Health Technology, Pharmaceuticals: Major, Manufacturing, Biological Product (except Diagnostic) Manufacturing

About FUSN

fusion pharmaceuticals (www.fusionpharma.com) is a new pharmaceutical company located in hamilton, ontario, canada, that is focused on becoming the leader in the targeted alpha therapy field. fusion will exploit its unique expertise in linking medical isotopes to targeting molecules to create highly effective therapeutics. in addition to its lead program, fpx-01, fusion is building a pipeline of products through a protein discovery platform, that allows for the rapid screening of new targeting molecules to promote biomarker localization of alpha emitting medical isotopes. fusion’s technology development team also has proprietary methods for introducing alpha emitters into targeting molecules.